| abstract |
5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]-methyl]-2,4-quinazolinedia mine (trimetrexate) has been shown to possess clinical activity against non-small cell lung cancer, head and neck squamous cancers, and breast cancer. The compound also demonstrates therapeutic synergy with several known antineoplastic agents. Methods of treating non-small cell lung cancer, head and neck cancers, and breast cancer by administering trimetrexate alone or in combination with other neoplastic agents is disclosed. |